Polysaccharide of Escherichia coli in the Prevention of Recurrent Urinary Tract Infection: An Evidence-Based Review

Manuel Tinoco, Mélody Santos, Conceição Reitor, Andreia Rodrigues, João Monteiro


Introduction: Recurrent urinary tract infection is frequent and it is related to morbidity, costs and growing antibiotic resistance. OM 8930 vaccine is composed by Escherichia coli polysaccharide and it is a possible prophylactic measure, but there is doubt as to its effectiveness.
Material and Methods: We performed a systematic review in evidence-based medicine databases with rigorous bibliography selection.
Results: We found an effective decrease of recurrences in test groups.
Discussion: We recommend the administration of the vaccine as prophylaxis of recurrent cystitis.
Conclusion: The vaccine has impact on the recurrent cystitis relapse rate. We suggest that more studies be carried out to evaluate the vaccine cost-benefit and its effectiveness in complicated urinary infections.


Adjuvants, Immunologic/therapeutic use; Escherichia coli Infections; Urinary Tract Infections; Uropathogenic Escherichia coli

Full Text:

PDF (Português)


  • There are currently no refbacks.